Homoharringtonine (Omacetaxine Mepesuccinate) in Patients With Chronic Myeloid Leukemia

Study Title
Homoharringtonine (Omacetaxine Mepesuccinate) in Treating Patients With Chronic Myeloid Leukemia (CML) With the T315I BCR-ABL Gene Mutation
Teva Identifier
CGX-635-CML-202 | 2006-000176-32
ClinicalTrials.gov Identifier
NCT00375219
Study Status
Completed
Trial Condition(s)
Chronic Myeloid Leukemia
Interventions
Drug: Omacetaxine mepesuccinate

Study Description

Please refer to ClinicalTrials.gov for a description of the trial
Print

Click for participation criteria and map of study locations


Key Participation Requirements

Gender
Female, Male
Age Range
18 Years and older
Trial Duration
09/01/2006 - 09/01/2013
Phase
Phase 2

Study Type

Interventional